KW 2449

Drug Profile

KW 2449

Alternative Names: KW-2449

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Kyowa Pharmaceutical
  • Developer Kyowa Hakko Kirin; Kyowa Pharmaceutical
  • Class Antineoplastics; Indazoles; Piperazines; Small molecules
  • Mechanism of Action Aurora kinase inhibitors; Bcr-abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 28 Jul 2010 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA (PO)
  • 30 Mar 2010 Suspended - Phase-I/II for Acute myeloid leukaemia in USA (PO)
  • 11 Dec 2007 Interim efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a Phase-I trial and a Preclinical trial in Cancer presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top